Blog

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= May 8, 2026 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

CertaraMay 8, 2026

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

CertaraMay 7, 2026

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

CertaraMay 7, 2026

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

CertaraMay 7, 2026

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

CertaraMay 7, 2026

On-Demand Webinar

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

Explore how Phoenix NLME and RsNLME support early phase clinical pharmacology workflows where speed, clarity,…

CertaraMay 6, 2026

Blog

GxP compliance in the cloud: What IT teams need to rethink

Learn how GxP validation works in modern SaaS and cloud environments, with best practices for…

CertaraMay 4, 2026

Webinar

ICH M13B Strength Biowaiver

CertaraApril 28, 2026

Blog

From models to impact: What QSPC 2026 revealed about the future of drug development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

CertaraApril 28, 2026

Blog

ADC dose optimization: Applying model-informed strategies in development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

Modeling and Simulation – PK/PD

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

Designing Drug Development Programs for Reimbursement Success

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

GxP compliance in the cloud: What IT teams need to rethink

ICH M13B Strength Biowaiver

From models to impact: What QSPC 2026 revealed about the future of drug development

ADC dose optimization: Applying model-informed strategies in development

Newsletter sign up

Quick links

Solutions

Contact